How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

根据提交给美国证券交易委员会的Form 4文件显示， RECURSION PHARMACEUTICALS, INC.（纳斯达克股票代码：RXRX） 首席财务官Ben R. Taylor于2025年12月29日以每股4.18美元的价格出售了21,383股A类普通股。此次交易总价值为89,380美元。

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

A new study published in the Journal of Autism and Developmental Disorders suggests that the ability to comprehend complex ...

How does market reflexivity amplify volatility? Learn why self-reinforcing feedback loops between investor belief and price action create explosive crypto bubbles and crashes.

Ahead of the MTG Lorwyn Eclipsed January 2026 launch, Wizards of the Coast revealed a wealth of cards that players can expect ...

One of the key learning outcomes of university education in general, and liberal arts programmes,  in particular, is that ...

Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.

The Arts Council of Princeton (ACP) has announced a three-person exhibition, “Divergent Forms,” featuring the work of artists ...